Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791518 · ClinicalTrials.gov registry record
Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
A clinical trial of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 1,084
- Enrollment target
- 20
- Study locations
NCT00791518: Completed study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
NCT00791518 is a study of Pulmonary Disease, Chronic Obstructive that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,084 participants, roughly in line with the 1,029-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target. The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00791518, a study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 1,084 participants
- Enrollment target
- 20
- Study locations
Study Summary
A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.
Primary Outcome
The percentage of participants on long-acting bronchodilator (LABD) monotherapy who had a post-albuterol FEV1) \<80% predicted normal was calculated. FEV1 is the amount of air that can be expelled from the lungs in one second after a full inspiration. Predicted normal values for FEV1 were calculated using the reference values from the third National Health and Nutrition Examination Survey (NHANES III). Values are based on the participants' age, height, sex, and race; thus, normal values vary bas
Conditions Studied
Interventions
- DRUG No intervention
Study Locations (20)
Florida
- GSK Investigational Site - Cocoa
- GSK Investigational Site - DeLand
- GSK Investigational Site - Largo
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Naranja
- GSK Investigational Site - South Miami
- GSK Investigational Site - Tamarac
- GSK Investigational Site - Tampa
California
- GSK Investigational Site - National City
- GSK Investigational Site - Rancho Mirage
- GSK Investigational Site - Riverside
- GSK Investigational Site - Santa Ana
- GSK Investigational Site - Walnut Creek
Colorado
- GSK Investigational Site - Colorado Springs
- GSK Investigational Site - Colorado Springs
Alabama
- GSK Investigational Site - Birmingham
Arizona
- GSK Investigational Site - Tucson
Arkansas
- GSK Investigational Site - Little Rock
Connecticut
- GSK Investigational Site - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,084 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-05 |
What the finished NCT00791518 record still lists
NCT00791518 is an observational study that tracks outcomes without assigning an intervention. Its 1,084 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,029-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT00791518 names 20 study sites across 7 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT00791518 about?
NCT00791518 is a clinical study titled "Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy". A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.
What is the current status of trial NCT00791518?
This trial is currently completed. The enrollment target is 1,084 participants. The study started on 2008-12. Estimated completion is 2009-05.
What conditions does trial NCT00791518 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00791518?
The interventions under investigation include: No intervention (DRUG).
Who is sponsoring clinical trial NCT00791518?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00791518 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00791518's enrollment target sits among peer trials
1,084 12th of 74 higher than 63 of 74 other Pulmonary Disease, Chronic Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 1
-
Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD
RECRUITING · NA
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06671483 · 1,088 participants · Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- NCT06074068 · 1,080 participants · NA
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
- NCT07213804 · 1,080 participants · Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
- NCT07196722 · 1,092 participants · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia